onc201
Safety of ONC201 administered two consecutive days per week in pediatric H3 K27M-mutant glioma patients
2021 SNO Annual Meeting Abstract CTNI-36
Chimerix is now part of Jazz Pharmaceuticals. Learn more at www.jazzpharma.com
